# Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9

> **NCT07678775** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ML Bio Solutions, Inc.** · enrollment: 107 (estimated)

## Conditions studied

- Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

## Interventions

- **DRUG:** BBP-418 (ribitol)

## Key facts

- **NCT ID:** NCT07678775
- **Lead sponsor:** ML Bio Solutions, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-05
- **Primary completion:** 2030-10
- **Final completion:** 2030-10
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678775, "Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*